214 related articles for article (PubMed ID: 19675743)
21. A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.
Choi DH; Shin DB; Lee MH; Lee DW; Dhandapani D; Carter D; King BL; Haffty BG
Cancer; 2003 Oct; 98(8):1587-95. PubMed ID: 14534873
[TBL] [Abstract][Full Text] [Related]
22. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
Maru D; Middleton LP; Wang S; Valero V; Sahin A
Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
[TBL] [Abstract][Full Text] [Related]
23. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
24. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
[TBL] [Abstract][Full Text] [Related]
25. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
Lateef F; Jamal S; Nasir S
J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
[TBL] [Abstract][Full Text] [Related]
26. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
27. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays.
Wang S; Saboorian MH; Frenkel E; Hynan L; Gokaslan ST; Ashfaq R
J Clin Pathol; 2000 May; 53(5):374-81. PubMed ID: 10889820
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer.
Marks JR; Humphrey PA; Wu K; Berry D; Bandarenko N; Kerns BJ; Iglehart JD
Ann Surg; 1994 Apr; 219(4):332-41. PubMed ID: 7909221
[TBL] [Abstract][Full Text] [Related]
29. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization.
Ross JS; Sheehan C; Hayner-Buchan AM; Ambros RA; Kallakury BV; Kaufman R; Fisher HA; Muraca PJ
Hum Pathol; 1997 Jul; 28(7):827-33. PubMed ID: 9224752
[TBL] [Abstract][Full Text] [Related]
30. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
31. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.
Bastacky S; Cieply K; Sherer C; Dhir R; Epstein JI
Hum Pathol; 2004 Mar; 35(3):281-9. PubMed ID: 15017583
[TBL] [Abstract][Full Text] [Related]
32. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
33. Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers.
Janocko LE; Brown KA; Smith CA; Gu LP; Pollice AA; Singh SG; Julian T; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Cytometry; 2001 Jun; 46(3):136-49. PubMed ID: 11449404
[TBL] [Abstract][Full Text] [Related]
34. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
Shukla S; Singh BK; Pathania OP; Jain M
Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
[TBL] [Abstract][Full Text] [Related]
36. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours.
Pan CC; Chen PC; Wang LS; Lee JY; Chiang H
Histopathology; 2003 Aug; 43(2):165-72. PubMed ID: 12877732
[TBL] [Abstract][Full Text] [Related]
37. Assessment of p53 and HER-2/neu genes status and protein products in oral squamous cell carcinomas.
Stoicănescu D; Andreescu N; Belengeanu A; Meszaros N; Cornianu M
Rom J Morphol Embryol; 2013; 54(4):1107-13. PubMed ID: 24399009
[TBL] [Abstract][Full Text] [Related]
38. Her-2/neu gene amplification compared with HER-2/neu protein overexpression on ultrasound guided core-needle biopsy specimens of breast carcinoma.
Kaya H; Ragazzini T; Aribal E; Güney I; Kotiloglu E
Pathol Oncol Res; 2001; 7(4):279-83. PubMed ID: 11882907
[TBL] [Abstract][Full Text] [Related]
39. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization.
Mark HF; Aswad B; Bassily N; Taylor W; Brown S; Sun CL; Samy M; Zolnierz K; Wong E; Bland KI; Hsu PH
Genet Med; 1999; 1(3):98-103. PubMed ID: 11336460
[TBL] [Abstract][Full Text] [Related]
40. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
